Company intelligence / Profile preview

Feng Gao

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

FengGao Biopharmaceutical is a clinical-stage biotechnology company based in China that specializes in the development of innovative metabolic and endocrine therapies. The company focuses on next-generation treatments for chronic conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). Its lead programs include multi-agonist peptides and small molecules targeting the GLP-1, GIP, and glucagon receptors. FengGao aims to provide more effective and convenient therapeutic options for patients with metabolic syndrome through advanced drug design and clinical validation.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on Feng Gao.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Feng Gao.

Explore the full profile